Background: Early natural menopause, the cessation of ovarian function before age 45 y, is positively associated
Introduction
Early menopause, which is the cessation of ovarian function before the age of 45 y, affects 10% of women in Western populations (1) . Women who experience early menopause Supported by UM1CA176726 and R01HD078517 from the NIH, US Department of Health and Human Services. Author disclosures: ACP-S, BWW, JEM, SEH, LMT, BAR, and ERB-J, no conflicts of interest. Supplemental Table 1 is available from the "Supplementary data" link in the online posting of the article and from the same link in the online table of contents at https://academic.oup.com/jn/. Address correspondence to ACP-S (e-mail: apurdues@umass.edu). are at increased risk of premature mortality and cognitive decline, osteoporosis, and cardiovascular disease, as well as other adverse health outcomes (2) (3) (4) (5) . Early menopause may also be problematic for couples trying to conceive, because female fertility declines drastically during the 10 y leading up to menopause (6) . Couples unable to conceive as they wish may experience substantial financial and psychological consequences, particularly as women increasingly delay childbearing into the later reproductive years (1, 7) . As such, it is important to identify modifiable lifestyle factors that may be related to early menopause risk, including diet.
Accelerated ovarian aging, the mechanism thought to underlie early menopause, is characterized by a decline in the quantity and quality of the ovarian follicle pool (7) . During the reproductive years, primordial follicle growth and transition to primary follicles are inhibited by anti-Müllerian hormone (AMH), a glycoprotein secreted by the granulosa cells of primary, secondary, and small antral follicles. Notably, a vitamin D response element has been identified in the promoter region of the AMH gene (8) , suggesting a potential role of vitamin D in AMH secretion and thus follicle recruitment. In line with this hypothesis, laboratory studies have shown that vitamin D upregulates AMH mRNA expression in both human prostate cells and granulosa cells of hens (9, 10) .
Findings of a recent study in the Nurses' Health Study (NHS) II (NHS2) cohort suggest that vitamin D intake from food sources, particularly dairy sources, is associated with a lower risk of early menopause (11) . Because vitamin D is obtained through dietary intake as well as sunlight exposure, concentrations of 25-hydroxyvitamin D [25(OH)D], the primary circulating metabolite of vitamin D, is a better indicator of vitamin D status than dietary intake alone. To our knowledge, no previous studies have evaluated 25 (OH)D concentrations and the risk of early menopause and findings of epidemiologic studies evaluating 25(OH)D concentrations and AMH are conflicting (12) (13) (14) (15) . One study found that AMH concentrations exhibit seasonal variation correlated with 25(OH)D concentrations and that vitamin D supplementation prevented a seasonal decline in AMH concentrations (13) . An additional study in US women found 25(OH)D to be positively associated with AMH concentrations (12) , whereas 3 morerecent studies reported no association (14, 15) .
It is also currently unclear whether measures of total compared with free 25(OH)D concentrations may have different relations with ovarian aging. At any given time, >99% of vitamin D in the body is bound to vitamin D-binding protein (VDBP) or albumin, leaving <1% unbound (16) . Because VDBP concentrations influence the bioavailability of vitamin D, assessing total compared with free 25(OH)D concentrations as well as concentrations of VDBP may be important for understanding the potential relation of vitamin D and early menopause. In fact, recent epidemiologic studies have observed that the free 25(OH)D fraction, as compared with total 25(OH)D, is more strongly associated with several health outcomes such as bone mineral density (17) and colorectal cancer (18) .
In light of the lack of studies evaluating vitamin D status and early menopause, the aims of the present nested case-control study were thus to evaluate associations of total 25(OH)D, free 25(OH)D, and VDBP concentrations and the risk of early menopause among participants of the NHS2.
Methods
The NHS2 is a prospective study in 116,429 female US registered nurses who were 25-42 y old in 1989 when they responded to a mailed baseline questionnaire. Information with regard to lifestyle behaviors and medical conditions are collected through biennial questionnaires, for which the follow-up rate for each cycle has been ≥89%. The study protocol was approved by the institutional review board at Brigham and Women's Hospital in Boston, Massachusetts.
Case and control ascertainment. On the 1989 baseline questionnaire, nurses were asked if their menstrual periods had ceased permanently (i.e., no periods for ≥12 mo) and were provided the following response options: 1) no (premenopausal), 2) yes (no menstrual periods), 3) yes (had menopause but now have periods induced by hormones), and 4) not sure (e.g., started hormones before cessation of periods). Nurses who indicated that their periods had ceased were then asked the following questions: 1) At what age did your periods cease (open response) and 2) for what reason did your periods cease (response options were surgery, radiation or chemotherapy, and natural)? Women were also asked about their current and past use of menopausal hormone therapy (HT). Questions with regard to menopausal status and use of HT were then repeated on all subsequent questionnaires.
A small number of women reported being postmenopausal on one questionnaire after a long interval of amenorrhea (>12 mo), only to have periods return again and report being premenopausal on a subsequent questionnaire. For these women, we defined age at menopause as the age after which periods were absent for ≥12 mo, and then confirmed that this status persisted for ≥3 consecutive questionnaires in order to reduce potential for misclassification of early menopause.
Blood sample collection. Participants of the NHS2 who had not previously been diagnosed with cancer (n = 92,888) were invited to provide blood samples between 1996 and 1999. During this time period, participants were aged 32-54 y. Premenopausal women who were not pregnant and were not using oral contraceptives (OCs) or menopausal HT were asked to provide 2 samples during the span of one menstrual cycle. The first sample was to be collected during the follicular phase (days 3-5 of the menstrual cycle) and the second was to be collected during the luteal phase (7-9 d before the start of the next menses). Women who were using OCs or menopausal HT were asked to provide a single untimed sample, and women who reported irregular menstrual cycles were asked to collect a luteal phase sample 22 d after the last menses. To confirm timing and menstrual cycle phase of the samples, women completed a postcard at the start of their next menses. Upon receipt, blood samples were centrifuged, separated into plasma, buffy, and RBC components, and then stored at ≤ -130°C in nitrogen freezers.
Among eligible women, 29,611 provided a sample and ∼23,000 of these women were premenopausal at the time of blood draw. Women who provided samples were similar to the entire NHS2 cohort, having equivalent BMI (in kg/m 2 ; 26 and 26) and parity (1.9 and 1.9 children) and comparable proportions of ever smoking (34% compared with 36%) and history of OC use (86% compared with 88%), as well as other factors (19) .
Because we were interested in prospectively evaluating the relation of plasma 25(OH)D concentrations and risk of early menopause, we limited eligibility to women who experienced menopause after blood draw. In addition, our study sample was limited to women without a previous diagnosis of cancer (other than nonmelanoma skin cancer), myocardial infarction, stroke, coronary artery bypass surgery, or percutaneous coronary intervention and women who had available plasma samples. Cases of early menopause were then defined as women reporting natural menopause (i.e., not due to surgery or chemotherapy) before the age of 45 y during follow-up. To reduce the potential for misclassification of early menopause status, eligible controls were women who experienced menopause after age 48 y (quartile 3 of the IQR). Eligible cases (n = 328) were then matched 1:1 to controls according to age at blood collection (within 4 mo), time of day of blood collection, month of collection (within 3 mo), sample type (luteal phase or untimed), and fasting status (Figure 1) Exclusions: cancer other than nonmelanoma skin cancer, death, loss-to-follow-up; declined participation in blood collection
Exclusions: confirmed cancer other than nonmelanoma skin cancer prior to blood draw; confirmed cardiovascular disease prior to blood draw; unavailable plasma; death; loss-tofollow-up; hysterectomy or oophorectomy before menopause; radiation or chemotherapyinduced menopause
Exclusions: confirmed cancer other than nonmelanoma skin cancer prior to blood draw; confirmed cardiovascular disease prior to blood draw; unavailable plasma; death; loss-to-followup; hysterectomy or oophorectomy before age 48 y; radiation or chemotherapy-induced menopause before age 48 y FIGURE 1 Participant flowchart. NHS2, Nurses' Health Study II.
equation (20):
To prevent potential exposure measurement error related to case status, laboratory personnel were blinded to case/control status for all assays. Samples were labeled by number; and matched case-control sets were handled together, shipped in the same batch, and assayed in the same analytical run. Masked quality-control samples were randomly interspersed among case-control samples and were analyzed in each batch. The CVs for biomarkers were 4.9% for total 25(OH)D, 7.2% for VDBP, and 8.6% for AMH.
Assessment of covariates. Variables used as matching factors,
including age at blood collection, time of day of blood collection, month of collection, sample type (luteal phase or untimed), and fasting status, were assessed at the time of blood draw. We also considered the following variables for inclusion in multivariable models on the basis of previous studies of risk factors for early menopause: race/ethnicity, smoking, BMI, parity, physical activity, OC use and duration, duration of breastfeeding, alcohol intake, and vegetable protein intake. Height and race/ethnicity were assessed at baseline in 1989 and information with regard to smoking status, weight (to calculate BMI), alcohol intake, fasting status, and menstrual cycle phase were collected at the time of blood draw by separate questionnaire. Updated information with regard to smoking, weight, OC use, parity, and breastfeeding was assessed on biennial questionnaires beginning in 1989. Physical activity was assessed in 1989, 1991, 1997, 2001 , and 2005 by using validated questionnaires (21) . Finally, validated FFQs administered every 4 y were used to assess dietary intake of total calories, alcohol, and vegetable protein (22) (23) (24) . Intakes of nutrients were adjusted for total energy using the residual method (25) . For time-varying covariates, we modeled variables that corresponded to questionnaires closest in time to blood collection for each individual. Women with missing covariate data were assigned to a missing indicator.
Statistical analysis. We used chi-square and t tests to compare characteristics of early menopause cases and controls at the time of blood draw and histogram and normality plots to assess the normality of biomarker data. Participants were divided into quartiles of total 25(OH)D, free 25(OH)D, and VDBP on the basis of the distribution of these biomarkers in the control group. Likelihood ratio tests comparing nested models were used to assess the global significance of each biomarker. We also categorized participants according to the following cutoffs: <50, 50 to <75, and ≥75 nmol/L (26). For analyses using continuous biomarker data, we identified and removed outliers by using the Rosner extreme studentized deviate test and standardized continuous variables to aid in interpretability. Relations of total and free 25(OH)D with log(AMH) were evaluated by using multivariable generalized linear models. We then back-calculated AMH geometric means and 95% CIs according to each quartile of total and free 25(OH)D.
For each exposure, we used conditional logistic regression to calculate ORs and 95% CIs, adjusting for matching factors only. We then controlled for potential confounders of the 25(OH)D-early menopause relation using multivariable conditional logistic regression. Because none of the covariates that were tested produced a change in exposure estimates >10%, covariates in multivariable models were selected if they were importantly associated with the outcome in our population.
To assess potential nonlinear associations of each biomarker exposure with the risk of early menopause, we additionally conducted restricted cubic spline models. For these models, we specified 4 knots in order to evaluate the individual spline term contributions to the model fit and overall test for nonlinearity.
We additionally used restricted cubic spline models to assess potential nonlinear associations of each biomarker with the risk of early menopause. To assess potential variation in associations according to age, we stratified our analyses by median age at blood draw (40 y). Second, because vitamin D is sequestered in adipose tissue (27) , we assessed potential BMI effect modification by stratifying according to 2 categories of BMI (<25 and ≥25). Third, to evaluate potential seasonal variation in the 25(OH)D-early menopause relation, we stratified our analyses by season of blood collection (winter/spring and summer/fall).
We also conducted sensitivity analyses to determine the robustness of estimates in primary analyses. Autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and lupus may be associated Vitamin D status and early menopause 1447 3 Values are means ± SDs. 4 Among ever smokers only. 5 Among ever OC users only.
with lower 25(OH)D concentrations and earlier age at menopause. Accordingly, we conducted analyses excluding individuals diagnosed with these conditions at any point during follow-up. Similarly, we conducted analyses limited to women with luteal phase samples in order to address the potential impact of variation in biomarker measures due to menstrual cycle variability. We also conducted analyses limited to never smokers to evaluate potential residual confounding due to misclassification of smoking amount among smokers. All of the analyses were conducted with the use of SAS version 9.4 software (SAS Institute, Inc.). We used 2-sided statistical tests performed at the 0.05 significance level for all analyses.
Results
Characteristics of cases and controls at the time of blood collection are presented in Table 1 . At the time of blood collection, cases were more likely to identify as nonwhite and to smoke and reported lower intakes of alcohol, supplemental calcium, and total vitamin D and calcium than controls.
In unadjusted analyses and analyses adjusting for important covariates, total 25(OH)D concentrations were not associated with risk ( Table 1 ). For each exposure, results from restricted cubic spline models indicated no associations with early menopause-either linear or nonlinear (P for all exposures >0.10; complete results not shown).
We did not find that adjusted geometric means of AMH concentrations varied according to quartile of total (P = 0.55) or free 25(OH)D (P = 0.32) concentrations ( Table 3) . AMH geometric mean concentrations varied significantly across VDBP quartiles, with the lowest concentrations in quartiles 3 and 4 (P = 0.04).
Findings of the primary analyses were largely unchanged in models evaluating effect modification and in sensitivity analyses. Estimates from analyses of total 25(OH)D stratified by median age at blood draw (<40 or ≥40 y) were consistent with findings from main analyses (data not shown). Estimates for total 25(OH)D stratified by BMI (underweight/normal and overweight/obese) were unstable due to small numbers (data not shown). Season (summer/fall compared with winter/spring) did not modify associations for total 25(OH)D or free 25(OH)D (P-interaction = 0.31 and 0.85, respectively). Estimates were also similar after restricting analyses to nonsmokers (n = 222 cases and 216 controls), women who provided timed blood samples (n = 254 cases and 254 controls), and women without diagnoses of autoimmune conditions (n = 321 cases and 319 controls). We also conducted models using only "super-normal controls," defined as women who experienced menopause at the population mean age of 51 y (n = 328 cases and 63 controls).
Estimates from these models were not materially different than those of our main analyses. For example, the MV1 OR for each 1-SD increase in total 25(OH)D was 1.29 (95% CI: 0.87, 1.91) and for free 25(OH)D was 1.00 (95% CI: 0.68, 1.46).
Discussion
In this prospective study, we did not find vitamin D metabolite concentrations to be consistently or strongly associated with the risk of early menopause, or with concentrations of plasma AMH, a marker of ovarian aging. Conversely, high compared with low VDBP concentrations were associated with increased risk of early menopause and lower AMH concentrations.
To our knowledge, this is the first study to investigate the association of total and free 25(OH)D and VDBP concentrations and risk of early menopause. A recent study in NHS2 participants by our research group observed a significant 17% lower risk of early menopause among women who consumed the highest vitamin D from food sources (quintile 5 median = 528 IU/d), as compared with those who consumed the least (quintile 1 median = 148 IU/d) (11) . In contrast, we observed that total vitamin D intake was not associated with risk, whereas supplemental vitamin D intake (≥600 compared with 0 IU/d) was associated with increased risk. The lack of strong and consistent associations of 25(OH)D with risk in 2 P values correspond to likelihood ratio tests comparing models with and without indicator variables for exposures. 3 ORs correspond to a 1-SD increase in exposure. 4 Model adjusted for matching factors only [i.e., age at blood collection (within 4 mo), time of day of blood collection, month of collection (within 3 mo), sample type (luteal phase or untimed), and fasting status].
the present analysis suggests that other dietary components or lifestyle factors correlated with vitamin D in foods may be associated with early menopause, rather than vitamin D itself. In our previous study, we noted a stronger association for dairy sources of vitamin D compared with nondairy dietary vitamin D. Other constituents of dairy, such as lactose, calcium, or progesterone, which are highly correlated with vitamin D in dairy, may have influenced the observed inverse association for dietary vitamin D. The potential importance of dairy foods generally, rather than vitamin D specifically, is also supported by findings of Carwile et al. (28) , who observed that low-fat dairy intake was associated with later age at menopause, among women aged <51 y. To answer this question, future studies of dairy foods and dairy constituents and risk of early menopause are warranted. Vitamin D has been hypothesized to be related to ovarian aging and menopause timing primarily through effects on AMH and follicular development. Our null findings for 25(OH)D and AMH are consistent with those of 3 cross-sectional studies (14, 15, 29) . Pearce et al. It is also possible that the 25(OH)D-AMH relation may vary across racial groups due to differences in VDBP, because VDBP concentrations and binding affinity are determined almost entirely by genetic polymorphisms specific to race and ethnicity (31) . The binding affinity and concentration of VDBP are directly related to the bioavailability of 25(OH)D within the body, and thus may be biologically relevant to the mechanisms involved in ovarian aging. In our study, we observed a threshold of higher risk for early menopause among individuals in quartiles 2 through 4 of VDBP compared with quartile 1, and a nonlinear relation of VDBP with AMH concentrations, suggesting that VDBP concentrations and/or their genetic determinants may be associated with risk. The NHS2, as well as the study populations of Pearce et al. (14) and Drakopoulos et al. (15) were almost entirely white, whereas that of Merhi et al. (12) was predominantly black and Hispanic. If 25(OH)D is only associated with AMH in specific racial/ethnic groups, demographic differences in study populations, and thus the underlying population heterogeneity of VDBP polymorphisms, may provide some explanation for inconsistent findings.
Our ability to evaluate associations of early menopause and AMH with free 25(OH)D and VDBP in nonwhite individuals was limited for 2 reasons. First, given the racial homogeneity of the NHS2, we used a monoclonal rather than a polyclonal assay to measure VDBP, which has been shown to underestimate free 25(OH)D concentrations in nonwhite individuals (32) . Second, the NHS2 is composed mostly of white women, and thus numbers of nonwhite individuals were too small to conduct race-stratified analyses. In light of evidence that the 25(OH)D-AMH relation may vary by race potentially due to VDBP differences, additional evaluation of 25(OH)D, VDBP, and AMH in large, diverse populations is necessary.
It is important to note additional limitations of our study. First, we relied upon single measurements of 25(OH)D, VDBP, and AMH. Because 25(OH)D concentrations are influenced heavily by recent sun exposure and dietary intake, it is possible that within-person variability in 25(OH)D concentrations may have contributed measurement error, resulting in nondifferential misclassification. However, in the NHS, a similar population of female health professionals, the intraclass correlation coefficient for plasma 25(OH)D measured 2-3 y apart was 0.72 (P < 0.001) (33) , and for measurements 10 y apart was 0.51 (95% CI: 0.42, 0.60) (34) . In a comparable population, the intraclass correlation coefficient for VDBP measured over 1-3 y was 0.96 (P < 0.001) (35) , indicating that these biomarkers are relatively stable over time. Furthermore, although some researchers have raised questions about potential misclassification of vitamin D deficiency status when 25(OH)D concentrations are measured by immunoassay, this technique is widely used and well validated for studies comparing disease risk across relative 25(OH)D concentrations, such as our study (36) . These factors help minimize the possibility that measurement error in biomarker data would explain our null findings for total and free 25(OH)D.
Second, we relied upon self-report of age at menopause, defined as the age at which periods were absent for 12 mo, to ascertain cases and controls. Because women may experience amenorrhea and then have periods return again during perimenopause, some degree of measurement error in selfreported age at menopause is to be expected. Such measurement error would result in misclassification of early menopause cases and controls and produce a bias toward the null. However, among 6591 women in the comparable NHS population, 82% of women reported the same age at menopause over multiple questionnaire cycles, suggesting high reproducibility (37) . Furthermore, we restricted the control group to women with age at menopause >48 y to reduce potential misclassification of the outcome. As such, misclassification of cases and controls would be an unlikely explanation for our findings.
Third, it is possible that residual confounding may have influenced our estimates. However, we were able to control for previously identified risk factors for early menopause such as smoking, vegetable protein intake, and BMI. None of the covariates included in multivariable models produced a change >10% in exposure estimates and unadjusted estimates were similar to fully adjusted estimates, suggesting that substantial bias due to residual confounding is unlikely.
There are also several notable strengths of our study, which extend on design limitations and findings of previous research in this area. First, this was the first study, to our knowledge, to evaluate the association of 25(OH)D and early menopause. Not only did we assess total 25(OH)D, we also evaluated VDBP and free 25(OH)D, which represents the biologically active vitamin D fraction and has been more strongly related to the risk of some health outcomes than total 25(OH)D alone. Second, the size of our study population was larger than previous studies evaluating 25(OH)D and AMH, which provided greater statistical power and also allowed us to consider a wide variety of potential confounders. Finally, because most previous studies of 25(OH)D and AMH have been conducted in women seeking treatment for infertility, we anticipate that our findings are more widely generalizable to healthy premenopausal women. In the context of our findings and those of the aforementioned studies, it appears that 25(OH)D is unlikely to be related to AMH or early menopause, at least among white premenopausal women without vitamin D deficiency.
In conclusion, the findings of our study do not suggest that 25(OH)D concentrations are importantly related to the risk of early menopause. Modest positive associations of VDBP concentrations with the risk of early menopause and AMH concentrations warrant further evaluation in large, ethnically diverse populations.
